Blood-Derived Products for Chronic Non-Healing Wounds

CMS nationally covers autologous PRP for treatment of chronic non-healing diabetic cutaneous wounds for up to 20 weeks when the PRP is prepared by devices with FDA-cleared indications for managing exuding cutaneous wounds. Autologous PDGF products and becaplermin for the specified non-covered wound types are not covered, and autologous PRP is not covered for acute surgical closed-incision or dehiscent wounds; coverage beyond 20 weeks and coverage for other chronic wound types is determined by local MACs.

"Autologous platelet-rich plasma (PRP) is covered for treatment of chronic non-healing diabetic cutaneous wounds for up to 20 weeks when prepared by devices with FDA-cleared indications for manageme..."

Sign up to see full coverage criteria, indications, and limitations.